Dipeptidyl peptidase IV inhibition exerts renoprotective effects in rats with established heart failure

Dipeptidyl peptidase IV inhibition exerts renoprotective effects in rats with established heart failure

Circulating dipeptidyl peptidase IV (DPPIV) activity is associated with worse cardiovascular outcomes in humans and experimental heart failure (HF) models, suggesting that DPPIV may play a role in the pathophysiology of this syndrome. Renal dysfunction is one of the key features of HF, but it remain...

Full description

Bibliographic Details
Main Authors:	Daniel Francisco De Arruda Junior, Flávia Letícia Martins, Rafael Dariolli, Leonardo Jensen Socas, Ednei Luiz Antonio, Leonardo Dos Santos, Paulo José Ferreira Tucci, Adriana Castello Costa Girardi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2016-07-01
Series:	Frontiers in Physiology
Subjects:	Glucagon-Like Peptide 1 fluid retention Megalin vildagliptin proteinuria. cardiorenal dysfunction
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fphys.2016.00293/full

Similar Items

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
by: Takatoshi Anno, et al.
Published: (2019-01-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

Rapamycin treatment induces tubular proteinuria: role of megalin-mediated protein reabsorption
by: Rodrigo A. S. Peres, et al.
Published: (2023-07-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
by: Vaia Lambadiari, et al.
Published: (2021-02-01)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
by: Bárbara Torrecillas-Baena, et al.
Published: (2023-07-01)

Molecular Docking of Compounds in Moringa oleifera Lam with Dipeptidyl Peptidase-4 Receptors as Antidiabetic Candidates
by: Indah Permata Rendi, et al.
Published: (2021-12-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
by: Chih-Tsung Hung, et al.
Published: (2022-11-01)

Renal Handling of Albumin—From Early Findings to Current Concepts
by: Jakub Gburek, et al.
Published: (2021-05-01)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney
by: Pavel Barta, et al.
Published: (2023-05-01)

Dipeptidyl Peptidase‐4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress
by: Enbo Zhu, et al.
Published: (2017-07-01)

Filtration and tubular handling of EWE‐hC3Nb1, a complement inhibitor nanobody, in wild type mice and a mouse model of proteinuric kidney disease
by: Morten Schøler Fast, et al.
Published: (2024-02-01)

Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes
by: Daiji Nagayama, et al.
Published: (2024-01-01)

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
by: Jaehyun Bae, et al.
Published: (2016-03-01)

Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus
by: I. V. Glinkina, et al.
Published: (2021-05-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury
by: Iman O. Sherif, et al.
Published: (2020-01-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
by: Dandan Zhao, et al.
Published: (2018-03-01)

Dipeptidyl peptidase IV (DDP IV) in NASH patients
by: Yasemin H. Balaban, et al.
Published: (2007-10-01)

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
by: Xin Jiang, et al.
Published: (2024-02-01)

Urinary megalin levels in patients with type 2 diabetic nephropathy and its correlation with renal function
by: Sudharshan Jagennath, et al.
Published: (2024-01-01)

Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study
by: Satoshi Shoji, et al.
Published: (2019-12-01)

Proximal Tubular Expression Patterns of Megalin and Cubilin in Proteinuric Nephropathies
by: Jia Sun, et al.
Published: (2017-07-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

Tackling dipeptidyl peptidase IV in neurological disorders
by: Ghaith Al-Badri, et al.
Published: (2018-01-01)

Dipeptidyl Peptidase IV as a Muscle Myokine
by: Heidi A. Kluess
Published: (2020-03-01)

Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review
by: Mutiu Kazeem, et al.
Published: (2021-06-01)

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats
by: Qian Zhang, et al.
Published: (2019-07-01)

Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01)

Renoprotective effects of teneligliptin: An observational study
by: Prabhat Agrawal, et al.
Published: (2021-01-01)

Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation
by: Taichi Ikedo, et al.
Published: (2017-11-01)

Urinary Iron Excretion is Associated with Urinary Full-Length Megalin and Renal Oxidative Stress in Chronic Kidney Disease
by: Shinya Nakatani, et al.
Published: (2018-03-01)

Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
by: T. B. Morgunova, et al.
Published: (2015-12-01)

DIPEPTIDYL DIPEPTIDASE-4: VIEW OF THE CLINICAL PHARMACOLOGIST
by: N. B. LAZAREVA
Published: (2016-12-01)